QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Defining Risk Minimisation Objectives and Implementation Pathways

Test your understanding of the concepts covered by GVP Module XVI: Defining Risk Minimisation Objectives and Implementation Pathways.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An evaluation shows that healthcare professionals understand the safety message but unsafe prescribing continues. What is the most appropriate next step?

Conclude that the measure is effective because knowledge increased Investigate barriers such as workflow, access, motivation or decision support and reconsider the objective or intervention Redistribute the same material without further analysis Shift all responsibility for the problem to patients

Question 2 of 10 A measure intended to reduce a medication error is evaluated only by the number of educational leaflets distributed. What is the main deficiency?

The measure has been evaluated using an implementation metric rather than evidence closer to the intended outcome Medication errors cannot be evaluated quantitatively Educational materials are never suitable for medication errors Distribution metrics always overestimate the number of errors

Question 3 of 10 Why should risk characterisation and risk minimisation be treated as related but distinct activities?

Risk characterisation determines the required legal wording, while risk minimisation concerns only communications Risk characterisation describes the safety problem, whereas risk minimisation determines what can reasonably be done about it Risk characterisation is performed only after the risk minimisation measure has been implemented Risk minimisation is required only for risks that have already been fully characterised

Question 4 of 10 Which statement best reflects appropriate QPPV oversight of risk minimisation?

The QPPV must personally conduct every distribution, training and implementation activity The QPPV should have visibility of significant decisions, responsibilities, proportionality and effectiveness, while operational tasks may be delegated The QPPV is responsible only for adverse event case processing The QPPV should approve every communication regardless of its significance

Question 5 of 10 Why must healthcare-system context be considered when planning implementation?

Because the same intervention may operate differently depending on prescribing, dispensing, administration and communication workflows Because national healthcare systems determine whether a safety concern exists Because implementation is independent of the product's conditions of use Because healthcare professionals should receive identical procedures regardless of setting

Question 6 of 10 When products supplied by different marketing authorisation holders have comparable risks, what is the most appropriate coordination principle?

Use identical measures in every circumstance, even when conditions of use differ Avoid coordination because each marketing authorisation holder has separate responsibilities Preserve consistency where the underlying risk and objective are shared while allowing justified product-specific differences Allow each company to use unrelated safety messages to avoid duplication

Question 7 of 10 Why can evaluating a measure for a rare but serious risk require emphasis on intermediate evidence?

Rare risks do not require effectiveness evaluation Clinical events may be too infrequent for simple outcome comparisons, making implementation and behavioural evidence informative while surveillance continues Intermediate evidence is always stronger than clinical outcome evidence Rare risks should be evaluated only through material distribution

Question 8 of 10 A known adverse reaction becomes more frequent in a specific patient subgroup despite existing product information. What is the most appropriate interpretation?

No new measure can be considered because the reaction is already listed The residual risk and limitations of existing controls should be reassessed, and a new measure may be justified The event should be removed from the RMP because it is already known The organisation should automatically impose a controlled-access system

Question 9 of 10 A serious reaction occurs mainly because prescribers initiate treatment in patients with a known contraindication. Which intervention principle is most relevant?

Focus primarily on post-treatment symptom recognition by patients Target the prescribing decision before exposure occurs Measure only the number of adverse event reports received Provide general safety information after treatment initiation

Question 10 of 10 What should national implementation of an EU-level risk minimisation requirement generally achieve?

Identical administrative procedures in every Member State regardless of healthcare structure Consistency in the underlying safety message and intended behaviour while allowing justified procedural adaptation Replacement of the scientific objective by national commercial preferences Removal of MAH oversight once a national process is established

QPPV.com

Knowledge Assessment: Defining Risk Minimisation Objectives and Implementation Pathways

Cookie Settings